PriceTargets.com logo

Zai Lab - ZLAB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.50
  • Forecasted Upside: 100.15%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$26.23 As of 11/20/2024 01:00 AM ET
▲ +0.08 (0.31%)

This chart shows the closing price for ZLAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zai Lab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZLAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZLAB

Analyst Price Target is $52.50
▲ +100.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Zai Lab in the last 3 months. The average price target is $52.50, with a high forecast of $66.00 and a low forecast of $44.00. The average price target represents a 100.15% upside from the last price of $26.23.

This chart shows the closing price for ZLAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Zai Lab. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/25/2024Cantor FitzgeraldReiterated RatingOverweight
10/21/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$38.00 ➝ $44.00
8/7/2024Cantor FitzgeraldReiterated RatingOverweight
7/12/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$43.00 ➝ $38.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight
6/25/2024Cantor FitzgeraldReiterated RatingOverweight
2/29/2024CitigroupLower TargetBuy ➝ Buy$123.00 ➝ $66.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/14/2023Morgan StanleyInitiated CoverageOverweight$47.50
11/30/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$64.00 ➝ $66.00
10/26/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$82.47 ➝ $73.34
10/26/2023CitigroupLower TargetBuy ➝ Buy$130.00 ➝ $128.00
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$67.00 ➝ $64.00
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00
8/10/2023Cantor FitzgeraldInitiated CoverageOverweight$70.00
6/12/2023Bank of AmericaLower Target$75.00 ➝ $62.50
5/11/2023CitigroupLower Target$138.00 ➝ $130.00
3/16/2023JPMorgan Chase & Co.Lower TargetOverweight$79.00 ➝ $70.00
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$96.00 ➝ $79.00
11/11/2022CitigroupLower TargetBuy$199.00 ➝ $127.00
10/20/2022GuggenheimLower Target$83.00
8/15/2022CitigroupBoost Target$199.00
8/9/2022CitigroupBoost TargetBuy$193.00 ➝ $199.00
5/12/2022CitigroupLower Target$198.00 ➝ $193.00
4/21/2022Leerink PartnersLower TargetOutperform$102.00 ➝ $101.00
4/4/2022JPMorgan Chase & Co.Lower TargetOverweight$136.00 ➝ $112.00
3/2/2022Leerink PartnersLower TargetOutperform$194.00 ➝ $102.00
1/21/2022MacquarieInitiated CoverageOutperform$64.00
12/15/2021JPMorgan Chase & Co.Lower TargetOverweight$189.00 ➝ $136.00
12/12/2021Leerink PartnersReiterated RatingBuy
12/3/2021CitigroupBoost TargetBuy ➝ Buy$217.00 ➝ $231.00
11/11/2021CitigroupLower TargetBuy$222.00 ➝ $217.00
11/10/2021Leerink PartnersLower TargetOutperform$200.00 ➝ $194.00
10/12/2021Sanford C. BernsteinInitiated CoverageMarket Perform
6/1/2021Leerink PartnersBoost TargetOutperform$192.00 ➝ $202.00
4/14/2021Leerink PartnersBoost TargetOutperform$183.00 ➝ $192.00
4/13/2021The Goldman Sachs GroupBoost TargetBuy$205.73 ➝ $211.23
4/13/2021GuggenheimBoost Target$165.00 ➝ $250.00
2/8/2021Jefferies Financial GroupBoost TargetBuy$130.00 ➝ $225.00
2/3/2021Leerink PartnersBoost TargetOutperform$107.00 ➝ $189.00
11/16/2020JPMorgan Chase & Co.Boost Target$101.00 ➝ $111.00
11/3/2020JPMorgan Chase & Co.Boost TargetOverweight$65.00 ➝ $101.00
9/10/2020Leerink PartnersBoost TargetOutperform$93.00 ➝ $95.00
8/14/2020GuggenheimBoost TargetPositive ➝ Buy$105.00 ➝ $111.00
7/8/2020GuggenheimBoost TargetBuy$75.00 ➝ $105.00
7/7/2020Leerink PartnersBoost TargetOutperform$79.00 ➝ $93.00
4/27/2020The Goldman Sachs GroupInitiated CoverageBuy
4/15/2020GuggenheimInitiated CoverageBuy$75.00
12/30/2019CitigroupBoost TargetBuy$65.00 ➝ $84.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 10 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
Mentions as of
4/24/2024
  • 15 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 12 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 12 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Zai Lab logo
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Read More

Today's Range

Now: $26.23
Low: $25.63
High: $26.77

50 Day Range

MA: $26.28
Low: $20.34
High: $33.18

52 Week Range

Now: $26.23
Low: $13.48
High: $36.60

Volume

1,384,654 shs

Average Volume

705,514 shs

Market Capitalization

$2.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Zai Lab?

The following equities research analysts have issued reports on Zai Lab in the last twelve months: Cantor Fitzgerald, Citigroup Inc., JPMorgan Chase & Co., and Morgan Stanley.
View the latest analyst ratings for ZLAB.

What is the current price target for Zai Lab?

0 Wall Street analysts have set twelve-month price targets for Zai Lab in the last year. Their average twelve-month price target is $52.50, suggesting a possible upside of 100.2%. Citigroup Inc. has the highest price target set, predicting ZLAB will reach $66.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $44.00 for Zai Lab in the next year.
View the latest price targets for ZLAB.

What is the current consensus analyst rating for Zai Lab?

Zai Lab currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZLAB will outperform the market and that investors should add to their positions of Zai Lab.
View the latest ratings for ZLAB.

What other companies compete with Zai Lab?

Other companies that are similar to Zai Lab include Qiagen, Revolution Medicines, Intra-Cellular Therapies, Roivant Sciences and Ascendis Pharma A/S. Learn More about companies similar to Zai Lab.

How do I contact Zai Lab's investor relations team?

Zai Lab's physical mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company's listed phone number is 862161632588 and its investor relations email address is [email protected]. The official website for Zai Lab is www.zailaboratory.com. Learn More about contacing Zai Lab investor relations.